Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 17/20 | 0.52 |
| ▸ | NOS1 | P29475 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5190108 | 0.83 | NOS2 (0.55) | NOS2NOS1ALDH1A1HSD17B10 | |
| SCHEMBL5190653 | 0.81 | NOS2 (0.59) | NOS2NOS1 | |
| SCHEMBL5189987 | 0.80 | NOS2 (0.61) | NOS2NOS1 | |
| SCHEMBL6296555 | 0.79 | NOS2 (0.48) | NOS2NOS1ALDH1A1HSD17B10 | |
| SCHEMBL5190007 | 0.78 | NOS2 (0.61) | NOS2NOS1 | |
| SCHEMBL5190116 | 0.78 | NOS2 (0.55) | NOS2NOS1ALDH1A1HSD17B10 | |
| SCHEMBL5193611 | 0.78 | NOS2 (0.69) | NOS2NOS1 | |
| SCHEMBL5190664 | 0.76 | NOS2 (0.62) | NOS2NOS1 | |
| SCHEMBL7612052 | 0.73 | NOS2 (0.56) | NOS2NOS1 | |
| SCHEMBL5194495 | 0.73 | NOS2 (0.60) | NOS2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6846829-B2 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2005-01-25 | — | — | US | disclosed |
| US-6670473-B2 | Inhibitors of nitric oxide synthase (nos) | BERLEX LABORATORIES, INC. | 2003-12-30 | — | — | US | disclosed |
| US-20030078265-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-04-24 | — | — | US | disclosed |
| US-20030060452-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-03-27 | — | — | US | disclosed |
| US-20030027794-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-02-06 | — | — | US | disclosed |
| US-20030004137-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-01-02 | — | — | US | disclosed |
| US-20020183323-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060452-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885NOS1 1/4885ALDH1A1 328/4885 |
| US-20030004137-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885NOS1 1/4885ALDH1A1 328/4885 |
| US-20030078265-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885NOS1 1/4885ALDH1A1 328/4885 |
| US-20030027794-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885NOS1 1/4885ALDH1A1 328/4885 |
| US-20020183323-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885NOS1 1/4885ALDH1A1 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.